RTsafe was founded in 2014 by medical physics professors, with considerable experience in the field of radiation oncology, aiming to address the issue of quality assurance in radiotherapy.
RTsafe expanded rapidly and established collaborations with renowned hospitals and academic institutions thanks to the exceptional teamwork of its experienced scientists and software developers. Our customers’ confidence in our products and services make us feel proud and inspire us to keep thinking forward and consistently improve the quality of our solutions.
We envisage a more efficient radiotherapy, the quality of which will be assured by more complete and strict procedures. Towards this direction, our vision is to implement truly patient-specific pretreatment plan verification for each and every patient, so as to eliminate the possibility of compromising the treatment outcome.
RTsafe produces Pseudo-Patient™ dosimetry phantoms, built from real patient anatomical data, by combining proven expertise in medical physics with highly accurate 3D printing technology.
Point, 2D or 3D dosimetry can be implemented using these dosimetry phantoms. Planning CT scanning, Treatment Planning, Set-up/Immobilization, Image Guidance and Treatment delivery are applied to the RTsafe Pseudo-Patients™ as if they are real living patients. This approach results in a true End-to-End QA testing that incorporates all links of the treatment chain.
2014Hellenic Entrepreneurship AwardOn 2nd June 2014, RTSafe was named one of the winners of the 2014 Hellenic Entrepreneurship Award.
20151st prize at MIT Enterprise Forum competitionRTsafe won the 1st prize of the MIT Enterprise Forum (MITEF) Greece Startup Competition.
2016RTsafe labs in SwitzerlandEstablishment of new offices and labs in Lausanne in order to support its operations in Switzerland.
2017RTsafe expands in the US marketSetup of a new subsidiary in San Antonio, Texas.